Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 5-dose Sabin IPV (msIPV)
NCT05386810Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Nov 2020
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (8 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Incidence of adverse reactions, Geometric Mean Titers and 1 more. Started Nov 2020; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT05386810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386810.